Primary source: Counsel Health newsroom, November 10, 2026
On November 10, 2026, Oura signed a definitive agreement to acquire Counsel Health for $625 million in cash. Counsel is the AI primary care company already in the ring app: a member chats with medical AI, and a board-certified physician can diagnose, prescribe, and refer. If you run revenue cycle, the visit just moved into a consumer product. The release does not say who sends the claim.
Cash, subject to purchase price adjustments. David Shuman, Oura’s executive chairman, said record growth this quarter is what gave the company confidence to invest $625 million cash. Expected to close before the end of the calendar year. It has not closed.
| Element | What November 10 published |
|---|---|
| Buyer | ŌURA. The Counsel newsroom calls it a health intelligence platform and the maker of the smart ring. The dateline is San Francisco. |
| Target | Counsel Health, “an AI-native primary care company,” founded and built by physicians and AI researchers. Medical AI plus in-house physicians. |
| Status | A definitive agreement. Not a close. The release says the transaction is “expected to close before the end of the calendar year, subject to customary closing conditions.” Oura’s blog says “near the end of this year.” |
| Price | “$625 million in cash, subject to purchase price adjustments.” Shuman, in the same release: “invest $625 million cash.” |
| The visit | A member starts from an Oura insight or chats with Counsel’s medical AI inside the Oura app. The AI draws on connected medical records, prior interactions, evidence-based guidelines, and continuous biometric data. The patient can add a board-certified Counsel physician, who can provide a diagnosis, prescriptions, and referrals. Oura’s blog adds that those physicians can diagnose, treat, order labs, and prescribe when appropriate. |
| Who already buys it | Health plans, health systems, consumer health organizations, and employers. After the deal, Counsel keeps serving existing and new partners, with the stated goal of reaching patients “beyond Oura’s member base.” |
| Oura’s quarter | Quarter ended Sept. 30, 2026: revenue $533 million, up 153% year over year. Adjusted EBITDA $87 million, a 16% margin. Fiscal 2026 revenue about $1.75 billion, up 92%. Shuman: “over six million members.” The release says these figures are preliminary, unaudited, and may change. |
| What the ring is | “Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.” |
Oura’s blog, published the same day, says the companies have partnered since May 2026 and that members can already try Counsel in Oura Labs. Physicians see Oura data and past conversations only with the member’s permission. Oura says more than half of Counsel users in Oura Labs have shared their ring data. That share is the company’s. So is the survey in the release, and it prints no sample size: among members using Counsel, more than 90 percent of those surveyed say their Oura data helped them get better care, and members who saw a Counsel physician rated the experience 4.6 out of 5.
TechCrunch, the same day, confirms the buyer, the target, and the $625 million. The price in this article is the release’s, not the reporter’s rounding.
The release describes the machinery under the chat. A clinical AI harness calls specialized agents for history-taking, guideline retrieval, records review, and emergency detection. Counsel says each agent is evaluated for performance, safety, and quality, and improved by feedback from its physicians. On the back end, physicians use a Clinician Cockpit, which the release calls an AI-native care delivery interface that “synthesizes a patient’s medical record and longitudinal health trend” and offers “context-aware clinical suggestions.” The three care areas named for the combined product are preventive, acute, and specialty and chronic, including reproductive health, aging, and cardiometabolic health.
Counsel’s About section, in the same release, says the model resolves “the majority of member needs within minutes,” and that by replacing nurse triage lines and telehealth it “helps partners reduce unnecessary downstream utilization, lower costs, and improve member engagement.” Those sentences are the company’s. They are not a deflection rate, a dollar of medical cost, or a payer contract.
“Over the past 10 years, our ring has gotten smaller and our platform has gotten bigger,” said David Shuman, executive chairman of Oura. “Oura’s record growth of 153 percent this quarter and our over six million members provides us the confidence to invest $625 million cash to acquire Counsel Health. Oura tells members what’s happening in their bodies, and Counsel helps them act on it. This combination expands our addressable market and deepens the value we deliver to every member. This not only increases lifetime value, but Counsel’s enterprise partners also open the door to millions of people beyond our existing member base. We are thrilled to welcome Muthu and the Counsel team to Oura.”
“Continuous health context makes medical AI more useful and relevant by delivering guidance that is personalized to each person’s health,” said Muthu Alagappan, MD, founder and chief executive officer of Counsel Health. “At Counsel, we’ve built medical AI around trust, safety and responsibility, keeping physicians in the loop for clinical decisions. Oura’s data gives clinicians objective context, trended biometrics, and member engagement to deliver more informed care. From the start, our teams bonded over a joint vision, shared culture, and mission, further solidifying as we negotiated our deal over the past few months. I am thrilled to join Oura to make high-quality care more accessible across a wide range of acute and chronic conditions.”
The $625 million can still move. The release subjects it to purchase price adjustments, and the close still depends on customary conditions. No Counsel revenue, valuation, or fee was disclosed, and none is estimated here. The $533 million is Oura’s preliminary quarter. It is not a base for a multiple of Counsel. The ring is not the clinician: the release says it is not a medical device. Counsel’s physicians are the ones who diagnose and prescribe. The release does not name a code, an EHR, a clearinghouse, a fee schedule, or who submits a claim when that physician prescribes, orders a lab, or refers. TechCrunch writes that the deal is expected to close before the end of 2027. The Counsel newsroom and Oura’s blog both put the close at the end of this calendar year. This article uses the release. TechCrunch, citing Bloomberg, reports that Alagappan will join as chief clinical AI officer and that Counsel has 70 employees. Neither the title nor the headcount is in the release or on Oura’s blog, and neither is treated as a deal term.
This is RevCycleAI’s read. Oura is spending consumer-wearable cash to own the step that used to happen in a clinic: a person looks at a body signal, and a physician acts. Shuman’s line is the product thesis. Oura tells members what is happening in their bodies, and Counsel helps them act on it. The act, in the release, is a diagnosis, a prescription, a referral. On Oura’s blog it is also a lab order. That is where a claim usually starts. These documents describe the act and stop.
The payer relationship is the part a revenue-cycle leader can actually use, and it is thin. Counsel already sells to health plans, health systems, and employers. Its About section says the point of replacing triage and telehealth is to cut downstream utilization and lower costs. If that holds, the ED, the specialist, and the follow-up visit those partners bill will see less volume. The release does not show a deflection rate, and it does not say the avoided visit was unnecessary. A health system that bills the downstream work and a plan that pays for it do not want the same outcome. The same morning, Charta raised $55 million to put one coding engine on both sides of a claim that already exists. This deal is earlier than that. There is no chart in the release to code.
The documentation path is the only place this touches the work a coding team does. The Clinician Cockpit synthesizes the record and the longitudinal trend before the physician decides. If that note is what a plan later audits, the words in it matter. The release does not say the note is written into an EHR, signed as the legal record, or attached to a claim. Oura’s blog says the physician sees ring data only with permission. A trend the member did not share is not in the chart.
The enterprise book is the open item. After the close, Counsel keeps its health-plan and health-system partners, including people who do not wear a ring. Shuman says those partners open the door to millions of people beyond the member base. He does not say those people generate a claim Oura will submit, a claim the clinic down the street will still submit, or a per-member fee that never becomes a claim at all. Until someone prints that, this is a care-delivery deal whose revenue-cycle consequence you cannot book.
Oura agreed to pay $625 million cash for the AI primary care layer inside the ring app. The release describes the visit. It does not describe the claim. The close is still this calendar year, and the $533 million quarter is preliminary.
Watch the order, not the ring. A Counsel physician who prescribes, orders a lab, or refers has just created work some revenue cycle may have to code. The release does not say whether that work is billed fee-for-service, absorbed in a health-plan or employer contract, or never billed. Ask that before you put this in a volume trend. The $625 million can still move on purchase-price adjustments, and the deal has not closed.
Who would bill the visit, what the release actually priced, and what it refused to say about payment.
Sources: Counsel Health newsroom, “Oura to acquire Counsel Health, advancing vision for more connected, personalized healthcare,” November 10, 2026, San Francisco (page opened); Oura, The Pulse Blog, “Oura Announces Agreement to Acquire Counsel Health,” November 10, 2026 (page opened); TechCrunch, Aisha Malik, “Oura to acquire AI-native primary care startup Counsel Health for $625M,” November 10, 2026 (page opened). Quotes from David Shuman and Muthu Alagappan are verbatim from the Counsel newsroom release. The $625 million cash price, the purchase-price adjustments, the calendar-year close, the $533 million quarter, the $87 million Adjusted EBITDA, the 16 percent margin, the about-$1.75 billion fiscal 2026 revenue, the 153 percent and 92 percent growth rates, the “over six million members,” the more-than-90-percent survey, the 4.6-out-of-5 rating, the enterprise-partner list, the Clinician Cockpit, the agent tasks, the three care areas, the “majority of member needs” line, the downstream-utilization sentence, and the not-a-medical-device sentence are the release’s. The May 2026 partnership, the permission rule, the “more than half” data-share line, the lab-order wording, and “near the end of this year” are Oura’s blog. TechCrunch’s end-of-2027 close date conflicts with those two primary sources and is not used as the close timing. The chief clinical AI officer title and the 70-employee figure are TechCrunch citing Bloomberg, and they are not in the release. The Business Wire URL for the same release timed out on fetch and is not quoted separately. An Investing.com page carrying a Reuters lead returned 403 and is not quoted. Axios Pro was not opened. No Counsel revenue, valuation, fee, code, or claim path was disclosed, and none is estimated. There is no prior RevCycleAI article on this deal.